LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

IMDx Receives Certification to Develop, Manufacture IVD Devices

By LabMedica International staff writers
Posted on 21 Jun 2012
Intelligent Medical Devices (IMDx; Cambridge, United Kingdom) has received International Organization for Standardization (ISO) certification to design, develop, and manufacture in vitro diagnostic devices for the diagnosis of infectious diseases in molecular biology, and will obtain licenses to commercialize the tests in Canada.

IMDx underwent a stringent audit of its quality system to ISO 13485:2003 with the implementation of requirements from the Canadian Medical Devices Regulations. The audit included quality management system development, documentation review, preaudit, initial assessment, and clearance. The ISO 13485:2003 accreditation was received from the Laboratoire national de métrologie et d’essais (LNE/G-MED) and is accepted worldwide as the inclusive international standard that defines quality in the area of medical devices.

The IMDx portfolio of infectious disease diagnostics includes CE-marked tests for toxigenic Clostridium difficile, vancomycin-resistant enterococci, and Group B Streptococcus.

“Receiving this certification is a true testament to our dedication to making high quality products,” says Dr. Alice Jacobs, MD, chairman and CEO of IMDx. “Our mission at IMDx is to make a wide range of diagnostic tests available as broadly as possible. The ability to eventually commercialize our tests in Canada brings us closer to achieving the goal of improving healthcare worldwide.”

Related Links:
International Organization for Standardization
IntelligentMDX




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control

Latest Industry News

New NHS Partnership Expands Access to Epigenetic CNS Tumor Classifiers
21 Jun 2012  |   Industry

Fujirebio Expands Access to Automated Blood-Based Neurology Testing in Canada
21 Jun 2012  |   Industry

Natera ctDNA Test to Support Response Monitoring in Solid Tumor Trial
21 Jun 2012  |   Industry